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Aim To determine the presence of circulating autoantibodies to de-
smoglein (Dsg) 1 and Dsg 3 in patients with oral lichen planus.
Methods Serum concentrations of circulating autoantibodies to Dsg 
1 and Dsg 3 were determined by ELISA in 32 patients with erosive 
form and 25 patients with reticular form of oral lichen planus, 13 pa-
tients with acute recurrent aphthous ulcerations and 50 healthy con-
trols. Indirect immunofluorescence analysis was also performed.
Results Concentrations of circulating autoantibodies to both Dsg 1 
and Dsg 3 detected in the sera of patients with erosive form of oral 
lichen planus were significantly increased in comparison with those 
in healthy controls, patients with recurrent aphthous ulceration, and 
those with reticular oral lichen planus (P<0.001 for both anti-Dsg 
autoantibodies). Indirect immunofluorescence also revealed signifi-
cantly more positive findings in patients with erosive oral lichen pla-
nus (18 positive of 22 tested) than in healthy controls (1 positive of 
20 tested; P<0.001), patients with recurrent aphthous ulceration (1 
positive of 10 tested; P<0.001), and those with reticular oral lichen 
planus (3 positive of 15 tested; P<0.001).
Conclusion Humoral autoimmunity seems to be involved in the 
pathogenesis of oral lichen planus. The differences in the serum con-
centration of desmoglein autoantibodies suggested that pathological 
mechanisms in erosive and reticular forms of oral lichen planus might 
not be the same.
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Oral lichen planus, a chronic disease and one 
of the most common dermatoses of the oral mu-
cosa, is characterized by white streaks in a lace-
like pattern on the tongue and/or buccal mu-
cosa. The disease is also accompanied by chronic 
inflammation the degree of which correlates 
with the intensity of the symptoms. The dis-
ease has several forms: atrophic, erosive, reticu-
lar, and bullous, with erosive form being the pre-
dominant initial presentation (1). The etiology 
of oral lichen planus is still poorly understood, 
but the disease is considered to be autoimmune 
(2,3). The precipitating factors can be stress, par-
ticular food, dental plaques, systemic illness, and 
poor oral hygiene (2). There is substantial evi-
dence that the pathogenesis of oral lichen pla-
nus involves a T-cell mediated process directed 
against basal keratinocytes (3-5), but no oral li-
chen planus-specific antigen has yet been iden-
tified. There is some evidence that humoral im-
munity may also be involved. Immunoglobulins, 
fibrinogen, and C3 complement may be present 
in the basement membrane within lesional and 
perilesional tissue (6), and levels of salivary IgG 
and IgA subclasses may also be altered (7). The 
presence of circulating antibodies to a lichen pla-
nus-specific antigen on the granular and deep ep-
ithelial prickle cells in the skin lesions of lichen 
planus was suggested (8), although the antigen it-
self was only infrequently demonstrated (9,10). 
The presence of antiepithelial antibodies was re-
ported in patients with oral and cutaneous lichen 
planus associated with drug therapy, but the an-
tibodies were generally present only in low con-
centrations (11). Ingafou et al (12) reported that 
oral lichen was not associated with IgG circulat-
ing antibodies to epithelial antigens. However, 
we have previously indicated the possibility of the 
presence of circulating antibodies to desmoglein 
1 and desmoglein 3 in patients with oral lichen 
planus (13). Autoantibodies to desmoglein 1 and 
desmoglein 3, desmosomal cadherins expressed 
in stratified squamous epithelia and involved in 
cell-to-cell adhesion (14), play a pathogenic role 
in autoimmune bullous diseases, causing disrup-
tion of desmosoms and consequent acantholysis 
(15). Commercial ELISA tests for desmoglein 1 
and desmoglein 3 autoantibodies are now avail-
able and have been proposed as a routine diag-
nostic tool (16). Although oral lichen planus and 
recurrent aphtohus ulceration manifest disparate 
clinical appearances and natural history, both of 
these oral mucosal diseases seem to share immu-
nopathological features that involve T-cell medi-
ated response to an antigenic stimulus in the epi-
thelium (17,18).
Our aim was to determine the presence of 
circulating autoantibodies to desmoglein 1 and 
desmoglein 3 in a group of patients with oral li-
chen planus and to compare them with healthy 




The study included 57 patients with oral li-
chen planus who were treated at the Department 
of Oral Medicine, Zagreb University School of 
Dental Medicine, from January 2001 to Octo-
ber 2004 (Table 1). The diagnosis of oral lichen 
planus was confirmed histopathologically. To ex-
clude patients with other similar diseases, such as 
pemphigus, mucous membrane pemphigoid, er-
ythema multiforme, and lupus erythematosus, 
direct and indirect immunofluorescence meth-
ods were applied. The presence of subepithelial 
deposits of fibrinogen and related substances by 
anti-fibrinogen antisera differentiated oral lichen 
planus from all other diseases except for lupus er-
ythematosus. The diagnosis of lupus erythemato-
sus was excluded by finding of globular pattern 
of subepithelial fibrin deposit in the absence of 
positive immunofluorescence with anti-immu-
noglobulin and anti-C1 antisera. Twenty-one of 
57 patients with oral lichen planus were receiving 
the following medications: non-steroidal anti-in-
flammatory drugs (1 patient), other analgesics (3 
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patients), antibiotics (2 patients), β-blockers and 
calcium channel blockers (6 patients), and other 
medications (15 patients). None had received im-
munosuppressive therapy 6 months before test-
ing.
Patients with recurrent aphthous ulceration 
were diagnosed according to the clinical crite-
ria for aphthae differentiation according to Leh-
ner (19). Eight patients had minor and 5 had 
major recurrent aphthous ulceration. None of 
the patients suffered from any systemic disease 
and none received any systemic or topical ther-
apy that could influence the results of tests per-
formed in this study.
A group of healthy controls consisted of 50 
apparently healthy volunteers.
Informed consent according to Helsinki Dec-
laration II was obtained from each subject before 
the study (20), and the study was approved by 
the Ethics Committee of the Zagreb University 
School of Dental Medicine.
Methods
Peripheral blood for determination of circu-
lating autoantibodies was drawn from each par-
ticipant between 8 am and 9 am. Serum was 
separated and stored in several samples at -20°C 
until use. Repeated freeze-thawing was avoided.
Determination of desmoglein autoantibodies
Commercial enzyme-linked immunosorbent 
assay (ELISA, Medical and Biological Laborato-
ries Co. Ltd, Nagoya, Japan) was used to deter-
mine autoantibodies to both desmogleins 1 and 
3 (MESACUP Desmoglein test [Dsg 1], Code 
No. 7680E, and [Dsg 3], Code No. 7685E). Ac-
cording to the manufacturer’s instructions, sera 
were diluted 100 × and tested in duplicate. Des-
moglein autoantibodies were determined by 
horseradish peroxidase-conjugated antihuman 
IgG with tetra-methylbenzidine as the substrate. 
The optical densities were read by the Dynatech 
MRX Microplate Reader at 450 nm, with 650 
nm reference filter. The results were presented 
in units per milliliter of sera (U/mL). The assay 
range was 5-150 U/mL, and reproducibility (co-
efficient of variability) was <15%.
Indirect immunofluorescence assay
Standard indirect immunofluorescence with 
monkey esophagus (indirect immunofluores-
cence IIFT Epidermis-esophagus, Code No. FA 
1501-1005, Euroimmun, Lubeck, Germany) and 
rat bladder (IIFT Transitional epithelium, Code 
No. FA 1507-1005, Euroimmun) as substrates 
was carried out to determine autoantibodies to 
epithelial antigens in subject’s sera. Fluorescein 
isothiocyanate-conjugated goat anti-human IgG 
specific for gamma chains was used as the second 
antibody. Patient sera were screened at a dilution 
of 1:20 in phosphate-buffered saline. All slides 
were assessed by two well-trained observers in a 
blinded fashion.
Statistical analysis
As the data did not show normal distribu-
tion, the results were presented as medians with 
interquartile ranges and analyzed by Kruskal-
Wallis test. Data on anti-desmoglein autoanti-
bodies were analyzed with Mann-Whitney U 
test, and data obtained by indirect immunoflu-
orescence were analyzed with χ2 test. On the ba-
sis of the observed differences, variability of the 
results, and group sample sizes, the comparisons 
achieved power between 0.78 and 0.99, with a 
significance level set at 0.05 using a two-sided 
Mann-Whitney tests and assuming that the ac-
tual distributions were double exponential. The 
statistical package used was Statistics with graph-
ics for Macintosh Version 1.0 (Data Metrics Inc., 
Philadelphia, PA, USA, 1985). P values <0.05 
were considered statistically significant.
Results
Concentrations of both anti-desmoglein 1 
and anti-desmoglein 3 autoantibodies in the pa-
tients with recurrent aphthous ulcerations and 
those with reticular form of oral lichen planus 
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were within the ranges found in healthy con-
trols (Table 1). Concentrations of both desmo-
glein autoantibodies were significantly higher in 
patients with erosive form of oral lichen planus 
than in healthy controls (P<0.001 for both au-
toantibodies), patients with recurrent aphthous 
ulceration (P<0.001 for both autoantibodies), 
and patients with reticular oral lichen planus 
(P<0.001 for both autoantibodies). Indirect im-
munofluorescence analysis using rat esophagus 
and/or rat bladder as substrates showed signifi-
cantly more findings positive to epithelial struc-
tures in patients with erosive oral lichen planus 
(18 positive of 22 tested) than in other three 
groups (Table 1). There was no difference in in-
direct immunofluorescence findings between the 
patients with recurrent aphthous ulcerations, pa-
tients with reticular form of oral lichen planus, 
and healthy controls (Table 1).
Discussion
Increased concentrations of both anti-des-
moglein 1 and anti-desmoglein 3 autoantibod-
ies, which were detected in the sera of patients 
with erosive form of oral lichen planus and con-
firmed by indirect immunofluorescence, indicat-
ed that anti-keratinocyte autoantibodies may be 
involved in pathogenesis of this clinical form of 
oral lichen planus. To the best of our knowledge, 
this is the first report on anti-desmoglein 1 and 
anti-desmoglein 3 circulating autoantibodies in 
patients with idiopathic oral lichen planus.
Ingafou et al (12) reported that oral lichen 
planus was not associated with IgG circulating 
antibodies to epithelial antigens. However, they 
used indirect immunofluorescence to determine 
autoantibodies to the epithelial components of 
monkey esophagus rather than desmoglein au-
toantibodies. We also performed indirect im-
munofluorescence using the same substrate and 
found 21 positive among 37 tested patients with 
oral lichen planus, ie, 2.5-fold more positive find-
ings in comparison with results reported by Inga-
fou et al (12). This difference might be attributed 
to different serum dilutions used for indirect im-
munofluorescence (1:100 dilution in Ingafou’s 
study vs 1:20 used in ours). However, these au-
thors found significantly more positive findings 
in patients with erosive than in those with retic-
ular form of oral lichen planus, which is in accor-
dance with our results. Increased concentrations 
of both desmoglein autoantibodies in patients 
with erosive form of oral lichen planus and sig-
nificantly higher proportion of indirect immu-
nofluorescence-positive findings in patients with 
erosive than in patients with reticular form of 
oral lichen planus might indicate significant dif-
ferences between these two clinical manifestation 
of oral lichen planus regarding their possible im-
munopathological features. In a previous study, 
we speculated that a new form of the disease may 
be manifested in the form of erosive oral lichen 
planus, or that overlapping of two diseases – ero-
sive lichen and an autoimmune bullous disease – 
might have occurred, as already reported by some 
Table 1. Characteristics, serum concentrations of autoantibodies to desmoglein 1 and 3, and indirect immunofluorescence findings in 57 
patients with oral lichen planus or recurrent aphthous ulceration, and healthy controls
No. of patients with
oral lichen planus recurrent aphthous
Characteristic* erosive (n = 32) reticular (n = 25) ulcerations (n = 13) controls (n = 50)
Age (median, range; y) 58 (30-72) 35 (20-52) 62 (40-74) 52 (19-70)
Sex (m/f)*  7/25  5/20  5/8 15/35
Smokers/non-smokers  6/28  4/21  –  6/44
Autoantibodies (U/mL, median, interquartile range)
 anti-Dsg 1 10.4 (4.9-16.3)†  2.3 (1.5-4.9)  3.0 (1.4-4.3)  2.9 (2.0-4.7)
 anti-Dsg 3  9.1 (3.3-12.9)†  2.4 (1.1-3.1)  1.5 (0.5-2.3)  2.9 (2.0-5.0)
 IIF (positive/tested) 18/22‡  3/15  1/10  1/20
*Abbreviations: m – male; f – female; Dsg – desmoglein; IIF – indirect immunofluorescence.
†P<0.001 vs other groups (Kruskal-Wallis test with Mann-Whitney post-hoc analysis).
‡P<0.001 vs other groups (χ2 test).
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authors (13,21,22). Presently, it is not clear if 
anti-desmoglein antibodies in erosive oral lichen 
planus could be of primary pathogenic signifi-
cance or might have appeared as the result of ep-
itope spreading process, known to be present in 
autoimmune diseases (23). During the process of 
antigen-specific (24,25) or non-specific (26) ke-
ratinocyte damage, antigenic material, including 
desmogleins, may be released and may elicit auto-
antibody generation. This process does not seem 
to be equally represented in erosive and reticular 
forms of oral lichen planus, as indicated by more 
prominent expression of anti-desmoglein auto-
antibodies in erosive form.
Patients with recurrent aphthous ulceration 
served as another control group because oral li-
chen planus and recurrent aphtohus ulceration, 
although different in clinical manifestation and 
natural history, seemed to share immunopatho-
logical features involving T cell-mediated immu-
nity (17,27). Our results indicate that these two 
diseases do not share similar features with respect 
to humoral immunity. Concentrations of both 
anti-desmoglein 1 and anti-desmoglein 3 anti-
bodies in patients with recurrent aphthous ulcer-
ation were in the range of those found in healthy 
controls. Only 1 of 10 patients with recurrent 
aphthous ulceration was indirect immunofluo-
rescence-positive when monkey esophagus was 
used as a substrate, whereas all were negative 
when rat bladder was used (data not shown).
In conclusion, humoral immunity against ke-
ratinocyte cadherins desmoglein 1 and desmo-
glein 3 seems to play a role in oral lichen planus. 
Significant differences in their serum concentra-
tions may be either indicative of different immu-
nopathogenic mechanisms involved in erosive 
and reticular oral lichen planus, or just reflect the 
differences in patophysiology of these two forms 
of oral lichen planus.
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